Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $7.53 for the day, down -1.18% from the previous closing price of $7.62. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 1.23 million shares were traded. OCUL stock price reached its highest trading level at $7.695 during the session, while it also had its lowest trading level at $7.41.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1197435648 and an Enterprise Value of 881118528. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.79 while its Price-to-Book (P/B) ratio in mrq is 3.77. Its current Enterprise Value per Revenue stands at 13.827 whereas that against EBITDA is -5.195.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.51, which has changed by -0.19119227 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is -0.46%, while the 200-Day Moving Average is calculated to be -10.10%.
Shares Statistics:
OCUL traded an average of 1.20M shares per day over the past three months and 1597850 shares per day over the past ten days. A total of 157.75M shares are outstanding, with a floating share count of 133.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 72.52% stake in the company. Shares short for OCUL as of 1741910400 were 12832340 with a Short Ratio of 10.05, compared to 1739491200 on 11601339. Therefore, it implies a Short% of Shares Outstanding of 12832340 and a Short% of Float of 8.1.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.26 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.05 and -$1.35 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.18, with 3.0 analysts recommending between -$1.06 and -$1.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $17.9M to a low estimate of $16.1M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $14.77MFor the next quarter, 10 analysts are estimating revenue of $17.7M. There is a high estimate of $18.5M for the next quarter, whereas the lowest estimate is $16.7M.
A total of 11 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $79.1M, while the lowest revenue estimate was $66.7M, resulting in an average revenue estimate of $71.01M. In the same quarter a year ago, actual revenue was $63.72MBased on 9 analysts’ estimates, the company’s revenue will be $79.91M in the next fiscal year. The high estimate is $100M and the low estimate is $68.7M.
